Silvia Ajossa

Silvia Ajossa

Auto-generated profile, based on publicly available information

Silvia Ajossa

Department of Surgical Sciences, Azienda Ospedaliera Universitaria Cagliari, Cagliari, Italy

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2018 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
GMGian Benedetto Melis
Gian Benedetto Melis
Manuela NeriManuela Neri
Manuela Neri
BPBruno Piras
Bruno Piras
APAnna Maria Paoletti
Anna Maria Paoletti
SASilvia Ajossa
Silvia Ajossa
Valerio MaisValerio Mais
Valerio Mais
Introduction: The medical strategy to antagonize myoma size and related-symptoms is to reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH agonist (GnRHa) or with compounds that antagonize progesterone stimulatory activity on myomas. Selective progesterone receptor modulators (SPRMs) bind progesterone receptor (PR), leading to both agonist and antagonist effects. The result of SPRMs’s action is tissue-specific and it depends on the particular affinity and strength of each SPRM. Area covered: Ulipristal acetate (UPA) is the first SPRM registered for myoma treatment. UPA reduces heavy uterine bleeding within 7 days from the onset of treatment, whereas a longer time is required with GnRHa treatment. Vilaprisan is a novel powerful SPRM. Phase I and II studies give encouraging results on the efficacy of vilaprisan at different doses. Like other SPRMs, vilaprisan induces benign changes of endometrium (PR modulator-associated endometrial changes, PAECs). These disappear as treatment is discontinued. Unlike GnRHa treatment, neither UPA nor vilaprisan induce hypoestrogenism and associated symptoms. Phase III studies are ongoing to confirm efficacy and safety of vilaprisan in long-term treatment of symptomatic fibroids. Expert opinion: It is fundamental to underline the rapidity of action (only 3 days) in the control of myoma-related bleeding.

1 March 2012 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
JAJuan Luis Alcazar
Juan Luis Alcazar
AIAlberto Iturra
Alberto Iturra
FSFederica Sedda
Federica Sedda
MAMaría Aubá
María Aubá
SASilvia Ajossa
Silvia Ajossa
MJMatías Jurado
Matías Jurado

23 August 2012 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
SGStefano Guerriero
Stefano Guerriero
MPM. Pilloni
M. Pilloni
JAJuan Luis Alcazar
Juan Luis Alcazar
FSF. Sedda
F. Sedda
SAS. Ajossa
S. Ajossa
Luca SabaLuca Saba
Luca Saba
Objectives To investigate differences in tissue characterization using three-dimensional sonographic mean gray value (MGV) between retrocervical and rectosigmoid deeply infiltrating endometriosis, and to assess intra- and interobserver concordance in MGV quantification. Methods In this retrospective study, stored ultrasound volumes from 50 premenopausal women (mean age, 32 years) with 57 histologically confirmed nodules of deep endometriosis were retrieved from our database for analysis. A single experienced operator had acquired all volumes. For each nodule, the MGV was evaluated using Virtual Organ Computer-aided AnaLysis (VOCAL) software with semiautomated sphere-sampling (1 cm3) from the central part of the nodule. In these patients the MGV was also quantified from the myometrium of the fundal part of the uterus. In addition, two observers calculated the MGV in a subset of 24 volumes in order to quantify inter- and intraobserver agreement using intraclass correlation coefficients (ICC). Results Mean MGV was significantly higher in rectosigmoid nodules (n = 34) than in nodules with a retrocervical location (n = 23) (23.863 vs 17.705; P < 0.001). MGV of the myometrium was significantly higher in comparison with that of nodules in both locations (P < 0.001 for both). Intra- and interobserver measurement reproducibility was excellent (ICC > 0.95). Conclusions Retrocervical and rectosigmoid endometriotic nodules display significantly different MGVs. Measurement of MGV is highly reproducible and its clinical value in the diagnosis and assessment of distribution of deep endometriosis should be assessed in future studies. Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd.

1 March 2011 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
JAJuan Luis Alcazar
Juan Luis Alcazar
SGStefano Guerriero
Stefano Guerriero
CLCarmen Laparte
Carmen Laparte
SASilvia Ajossa
Silvia Ajossa
MJMatías Jurado
Matías Jurado

1 March 2019 in Gynecological Endocrinology
Verified
Journal Article
Closed access
Manuela NeriManuela Neri
Manuela Neri
MPMonica Pilloni
Monica Pilloni
APAnna Maria Paoletti
Anna Maria Paoletti
GMGian Benedetto Melis
Gian Benedetto Melis
BPBruno Piras
Bruno Piras
Valerio MaisValerio Mais
Valerio Mais
This observational study was conducted in premenopausal women who presented themselves at the Obstetrics and Gynecology Department of the University Hospital of Cagliari (Italy), for heavy menstrual bleeding (HMB) dependent on uterine myomas. After a screening visit, 19 women without contraindications to ulipristal acetate (UPA) treatment, were included in the study that envisaged 12 months of observation in which each subject was asked to assume UPA (tablet of 5 mg, ESMYA®, one tablet a day for 3 months: first cycle) two menstrual cycles of interruption and a second ESMYA® cycle, followed by 3 months of observation (third follow-up month, visit 4). The significant decrease of myoma volume, diagnosed after the first ESMYA® cycle, persisted until the visit 4. The HMB significantly decreased during the ESMYA® treatment and persisted until visit 4. The quality of life (QoL), evaluated with the questionnaire SF-36, significantly improved during the study. The values of estradiol (E2), biochemical parameters of bone metabolism, as well as those of lumbar and hip bone mineral density, did not change during the study in comparison with basal levels. The efficacy of two repeated ESMYA® cycles to treat uterine myomas and their related symptoms improves the QoL without interfering with bone health.

1 March 1995 in Fertility and Sterility
Verified
Journal Article
Closed access
VMValerio Mais
Valerio Mais
SASilvia Ajossa
Silvia Ajossa
SGStefano Guerriero
Stefano Guerriero
APAnna Maria Paoletti
Anna Maria Paoletti
GMGian Benedetto Melis
Gian Benedetto Melis